Argenx is a global, commercial-stage biopharmaceutical company focused on developing and delivering transformative therapies for patients with severe autoimmune diseases. They leverage their expertise in immunology and antibody engineering to create a pipeline of novel antibody-based medicines, with a flagship product, Vyvgart (efgartigimod alfa), approved for conditions like generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.